Business Context and Reporting Period
Company: Monopar Therapeutics Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 20, 2022
Reporting Period: Event date of April 20, 2022.
Business Context: The Company is an emerging growth company incorporated in Delaware, with its principal executive offices in Wilmette, IL. It trades on the Nasdaq Capital Market under the symbol MNPR.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on a new financing arrangement.
- Proposed Capital Raise: Up to $4,870,000 in aggregate gross proceeds.
- Instrument: Shares of Common Stock, $0.001 par value.
- Agent Commission: Up to 3% of gross proceeds from the sale of shares.
Material Changes
On April 20, 2022, Monopar entered into a "Capital on Demand" Sales Agreement with JonesTrading Institutional Services LLC. This agreement allows the Company to offer and sell shares of its Common Stock from time to time through an "at the market" offering. The Company is not obligated to sell any shares under this agreement. The offering will terminate upon the sale of all shares subject to the agreement or earlier termination by either party.
Guidance, Outlook, and Risks
Management Commentary: The Company filed a prospectus supplement relating to the offer and sale of shares pursuant to a shelf registration statement (File No. 333-235791) originally filed in January 2020.
Risks and Contingencies:
- Sales are subject to market conditions and the discretion of the Company.
- The offering is subject to applicable state and federal laws and Nasdaq Capital Market rules.
- The Company has agreed to provide customary indemnification and contribution rights to the agent.
Investor Verification Checklist
- Verify the current market price of MNPR to assess potential dilution from the $4,870,000 offering.
- Review the full text of the Sales Agreement (Exhibit 1.1) for specific termination rights and conditions.
- Confirm the Company's current cash position in the most recent 10-Q or 10-K to understand the necessity of this capital raise.
- Check for any subsequent filings indicating the actual volume of shares sold under this agreement.